Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain

Abstract

In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use.